PlaqueTec
Develops AI-driven precision medicine tools aimed at improving assessment and management of cardiovascular disease by supporting personalized diagnosis and treatment decisions.
Overview
PlaqueTec develops AI-driven precision medicine solutions focused on cardiovascular disease, positioning its products to support more personalized assessment and management of cardiac conditions. The company emphasizes precision medicine for cardiovascular care and markets its technology to stakeholders involved in diagnosis and treatment of heart disease. PlaqueTec is an early-stage, Cambridge-based venture that completed an undisclosed financing of €4.2 million (reported as $5M total raised) on April 27, 2026 to advance its precision medicine work in cardiovascular disease.
Funding History
Cambridge’s PlaqueTec raises €4.2 million to advance precision medicine for cardiovascular disease
Frequently Asked Questions
- How much has PlaqueTec raised in total?
- PlaqueTec has raised a total of $5M across 1 funding round.
- Who are PlaqueTec's investors?
- PlaqueTec's investors include Undisclosed.
- What does PlaqueTec do?
- PlaqueTec develops AI-driven precision medicine solutions focused on cardiovascular disease, positioning its products to support more personalized assessment and management of cardiac conditions. The company emphasizes precision medicine for cardiovascular care and markets its technology to stakeholders involved in diagnosis and treatment of heart disease. PlaqueTec is an early-stage, Cambridge-based venture that completed an undisclosed financing of €4.2 million (reported as $5M total raised) on April 27, 2026 to advance its precision medicine work in cardiovascular disease.
- Where is PlaqueTec headquartered?
- PlaqueTec is headquartered in Cambridge, United Kingdom.
Investors
Related Insights
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $35.9 billion raised across 95 deals, with 15 mega-rounds capturing 85.5% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
The AI Healthcare sector is one of the most dynamic areas of AI investment in 2026. This report profiles the top-funded startups in the space, their investors, and the market dynamics driving growth.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.